Clinicopathologic Characteristics and Therapeutic Outcomes of Primary Gastrointestinal Non-Hodgkin's Lymphomas: 10 Years of Experience from a Single Center in Eastern Anatolia
dc.authorid | KAYA, Emin/0000-0001-8605-8497 | |
dc.authorid | Erkurt, Mehmet Ali/0000-0002-3285-417X | |
dc.authorwosid | Basaran, Yalcin/D-7227-2017 | |
dc.authorwosid | KAYA, Emin/W-2951-2017 | |
dc.authorwosid | Erkurt, Mehmet Ali/ABI-7232-2020 | |
dc.contributor.author | Erkurt, Mehmet Ali | |
dc.contributor.author | Aydogdu, Ismet | |
dc.contributor.author | Kuku, Irfan | |
dc.contributor.author | Kaya, Emin | |
dc.contributor.author | Basaran, Yalcin | |
dc.date.accessioned | 2024-08-04T20:31:16Z | |
dc.date.available | 2024-08-04T20:31:16Z | |
dc.date.issued | 2009 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | Objective: The objective of this retrospective study was to report the clinicopathological data and the treatment outcomes in patients with primary gastrointestinal non-Hodgkin's lymphoma. Patients and Methods: We carried out a retrospective analysis of 41 patients (22 females, 18 males, median age 58 and range 18-90 years) who presented to our department with histopathological diagnosis of primary gastrointestinal non-Hodgkin's lymphoma between 1995 and 2004. Results: The stomach was the most common extranodal site and was seen in 25 of 41 (61%) patients. At presentation 28 (68.3%) patients had gastrointestinal symptoms while 27 (65.9%) had B symptoms. The range of follow-up was 2-84 months with a median of 9 months. The overall survival rate was 3 years for 25 (61.2%) patients. The 3-year overall survival rate was better in patients with early-stage disease (stages I and II1) who were treated with surgery plus chemotherapy and/or radiation therapy than in those treated with chemotherapy alone (91.6 vs. 50%, p < 0.05). The disease had a significant impact on both the progression-free survival and overall survival rates. Conclusion: Our data showed that surgical resection prior to postoperative chemotherapy was a better option for patients with early-stage disease with better patient survival. Copyright (C) 2009 S. Karger AG, Basel | en_US |
dc.identifier.doi | 10.1159/000226295 | |
dc.identifier.endpage | 406 | en_US |
dc.identifier.issn | 1011-7571 | |
dc.identifier.issn | 1423-0151 | |
dc.identifier.issue | 5 | en_US |
dc.identifier.pmid | 19648764 | en_US |
dc.identifier.scopus | 2-s2.0-68249153474 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 399 | en_US |
dc.identifier.uri | https://doi.org/10.1159/000226295 | |
dc.identifier.uri | https://hdl.handle.net/11616/94848 | |
dc.identifier.volume | 18 | en_US |
dc.identifier.wos | WOS:000268678200011 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Karger | en_US |
dc.relation.ispartof | Medical Principles and Practice | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Gastrointestinal non-Hodgkin's lymphoma | en_US |
dc.subject | Prognostic factors | en_US |
dc.subject | Clinicopathologic features | en_US |
dc.subject | Survival | en_US |
dc.title | Clinicopathologic Characteristics and Therapeutic Outcomes of Primary Gastrointestinal Non-Hodgkin's Lymphomas: 10 Years of Experience from a Single Center in Eastern Anatolia | en_US |
dc.type | Article | en_US |